Indium (111In) capromab pendetide

Indium (111In) capromab pendetide
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	151763-64-3
PubChem
DrugBank
ChemSpider	none
KEGG

Indium (¹¹¹In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.<ref name="PMID 18279057">,

 Indium-111 capromab pendetide in the management of recurrent prostate cancer, 
 Expert Review of Anticancer Therapy, 
 2008,
 Vol. 8(Issue: 2),
 pp. 175–81,
 DOI: 10.1586/14737140.8.2.175,
 PMID: 18279057,</ref> Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.<ref>WHO Drug Information</ref> Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).<ref name=" PMID 18279057" />

Early trials with yttrium (⁹⁰Y) capromab pendetide were also conducted.<ref>Kahn, Daniel,

 A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy, 
 Cancer Biotherapy & Radiopharmaceuticals, 
 1999,
 Vol. 14(Issue: 2),
 pp. 99,
 DOI: 10.1089/cbr.1999.14.99,</ref>

References

Stub icon

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!